J
Jörg Schubert
Researcher at Saarland University
Publications - 29
Citations - 3006
Jörg Schubert is an academic researcher from Saarland University. The author has contributed to research in topics: Eculizumab & Paroxysmal nocturnal hemoglobinuria. The author has an hindex of 11, co-authored 27 publications receiving 2737 citations. Previous affiliations of Jörg Schubert include Hamm AG.
Papers
More filters
Journal ArticleDOI
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Peter Hillmen,Neal S. Young,Jörg Schubert,Robert A. Brodsky,Gérard Socié,Petra Muus,Alexander Röth,Jeff Szer,Modupe O. Elebute,Ryotaro Nakamura,Paul Browne,Antonio M. Risitano,Anita Hill,Hubert Schrezenmeier,Chieh Lin Fu,Jaroslaw P. Maciejewski,Scott A. Rollins,Christopher F. Mojcik,Russell P. Rother,Lucio Luzzatto +19 more
TL;DR: Eculizumab is an effective therapy for PNH and Clinically significant improvements were found in the quality of life, as measured by scores on the Functional Assessment of Chronic Illness Therapy-Fatigue instrument and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire.
Journal ArticleDOI
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Robert A. Brodsky,Neal S. Young,Elisabetta Antonioli,Antonio M. Risitano,Hubert Schrezenmeier,Jörg Schubert,Anna Gaya,Luke Coyle,Carlos M. de Castro,Chieh Lin Fu,Jaroslaw P. Maciejewski,Monica Bessler,Henk André Kroon,Russell P. Rother,Peter Hillmen +14 more
TL;DR: The beneficial effects of eculizumab treatment in patients with PNH are applicable to a broader population of PNH patients than previously studied and were independent of baseline levels of hemolysis and degree of thrombocytopenia.
Journal ArticleDOI
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.
Peter Hillmen,Petra Muus,Ulrich Dührsen,Antonio M. Risitano,Jörg Schubert,Lucio Luzzatto,Hubert Schrezenmeier,Jeff Szer,Robert A. Brodsky,Anita Hill,Gérard Socié,Monica Bessler,Scott A. Rollins,Leonard Bell,Russell P. Rother,Neal S. Young +15 more
TL;DR: Results show that eculizumab treatment reduces the risk of clinical thromboembolism in patients with PNH.
Journal ArticleDOI
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.
Peter Dreger,Hartmut Döhner,Matthias Ritgen,Sebastian Böttcher,Raymonde Busch,Sascha Dietrich,Donald Bunjes,Sandra Cohen,Jörg Schubert,Ute Hegenbart,Dietrich W. Beelen,Matthias Zeis,Michael Stadler,Justin Hasenkamp,Lutz Uharek,Christof Scheid,Andreas Humpe,Thorsten Zenz,Dirk Winkler,Michael Hallek,Michael Kneba,Norbert Schmitz,Stephan Stilgenbauer +22 more
TL;DR: In conclusion, alloSCT for poor-risk chronic lymphocytic leukemia can result in long-term MRD-negative survival in up to one-half of the patients independent of the underlying genomic risk profile.
Journal ArticleDOI
Role of Radiotherapy to Bulky Disease in Elderly Patients With Aggressive B-Cell Lymphoma
Gerhard Held,Niels Murawski,Marita Ziepert,Jochen Fleckenstein,Viola Pöschel,Carsten Zwick,Jörg Thomas Bittenbring,Mathias Hänel,Sibylla Wilhelm,Jörg Schubert,Norbert Schmitz,Markus W. Löffler,Christian Rübe,Michael Pfreundschuh +13 more
TL;DR: Additive RT to bulky sites abrogates bulky disease as a risk factor and improves outcome of elderly patients with aggressive B-cell lymphoma.